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Introduction: Hyperhomocysteinemia is a known risk factor for myocardial infarction, stroke, peripheral vascular
disease, and thrombosis. Elevated plasma homocysteine levels have been demonstrated in patients with recurrent
episodes or a single episode of thrombosis. Here we describe the development of cardiovascular disease as a
complication of a surgical intervention in a patient with colorectal cancer and hyperhomocysteinemia.
Case presentation: A 65-year-old Caucasian man complained of pain and constipation, attributed to previously
diagnosed adenocarcinoma (stage IIB) of the hepatic flexure. An anamnestic investigation showed that he had
undergone two surgical interventions. During both, he suffered thrombotic postoperative complications, a deep
vein thrombosis of the upper extremity after the first operation and retinal vein occlusion after the second. He was
diagnosed with hyperhomocysteinemia associated with a homozygous C677T mutation of the gene encoding the
enzyme methylenetetrahydrofolate reductase. Our patient was initially treated with folic acid and high-dose B
vitamins. On day 7 he underwent a right hemicolectomy. Anesthesia was performed with sevoflurane in 40% O2
and without the use of nitrous oxide. Postoperatively, our patient remained on folic acid and B vitamins and was
without immediate or subsequent complications.
Conclusions: Neoplastic disease and related surgery followed by the administration of chemotherapeutic drugs
alter the hemostatic balance in cancer patients. Those suspected of also having a thrombophilic disease require a
thorough laboratory diagnostic workup, including a molecular analysis aimed at identifying the genetic mutation
responsible for the hyperhomocysteinemia, as indicated. The case described in this report highlights the
importance of a multidisciplinary approach that includes expertise in peri-operative anesthesia, surgery, oncology,
and hematology.* Correspondence: m.cascella@istitutotumori.na.it
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Clinical and epidemiological studies have shown that al-
terations in homocysteine (Hcy) metabolism play a role
in atherosclerosis [1–3]. This would explain the approxi-
mately 20% of patients with atherosclerotic vascular dis-
ease but without any known cardiovascular risk factors,
such as a family history, diabetes, smoking, and high
blood pressure [4].
Hcy is a sulfur-containing amino acid that is formed
during the methionine (MET) cycle. MET is an essential
amino acid present in proteins of animal origin. Dietary
MET is converted from adenosyltransferase methionine
to S-adenosylmethionine (SAM). As the major donor of
the methyl groups required in transmethylation reac-
tions, SAM is critical to the synthesis of proteins, nucleic
acids, creatinine, phospholipids, and neurotransmitters.
The plasma level of Hcy is controlled by two distinct
metabolic pathways. In the first, Hcy is degraded to cyst-
eine, which is eliminated via the kidney; in the second,
Hcy is converted to MET through a methylation reac-
tion in which Hcy acquires a methyl group from either
N5-methyltetrahydrofolate (MTHF) or from betaine and
is then reconverted to MET. MET methylation is cata-
lyzed by MET synthase using vitamin B12 as a cofactor
and MTHF as the methyl donor. MTHF is formed from
folic acid by the enzyme N5, N10 methylenetetrahydro-
folate reductase (MTHFR).This MET recovery pathway
contributes to regulating the serum Hcy concentration,
and alterations therein underlie the development of
Hcy-related atherosclerosis [5].
Under normal conditions, there is a close balance be-
tween the formation and elimination of Hcy, with ap-
proximately 50% being methylated to MET. In the
presence of excess MET, a larger amount is converted to
cysteine via a transulfuration reaction. If the rate of cel-
lular Hcy formation is faster than the rate of Hcy con-
sumption, the excess is released into the circulation,
leading to hyperhomocysteinemia (HHcy).
A possible cause of HHcy is the presence of genetic ab-
normalities that affect both the sulfuration reaction and
the methylation of Hcy to MET. Two known MTHFR
polymorphisms are associated with the reduced activity of
the enzyme and therefore with increased levels of Hcy: the
C677T polymorphism and the A1298C polymorphism. Of
these, the former is considered the most important genetic
determinant of Hcy concentrations.
MTHFR mutations are relatively common. For example,
homozygosity for MTHFR C677T is present in 0–3% of
African Americans and in 9–11% of Caucasian Americans.
These mutations may remain undetected but they are also
associated with an increased incidence of thrombotic dis-
eases. However, in rare cases defects in MTHFR cause se-
vere increases in plasma Hcy, leading to gait abnormalities,
seizures, and psychiatric manifestations. Here we describethe development of cardiovascular disease as a complica-
tion of a surgical intervention in a patient with colorectal
cancer and hyperhomocysteinemia.
Case presentation
A 65-year-old Caucasian man complained of pain and
constipation related to adenocarcinoma (stage IIB) involv-
ing the hepatic flexure. He had a long-standing history of
hypertension, but it was well controlled with a beta
blocker. An anamnestic investigation showed that he had
been operated on twice: approximately 10 years earlier he
had undergone surgical repair of an inguinal hernia, and 2
months earlier, a transurethral resection for a papilloma-
tous lesion of the bladder. Following both surgeries, he
had symptoms indicative of thrombotic complications.
The first operation was followed by the rapid onset of
postoperative pain in the left arm, with swelling and red-
ness. These symptoms lasted for approximately 1 month
and were treated with antibiotics and low-molecular-
weight heparin. His symptoms suggested a deep vein
thrombosis (DVT) of the upper extremity, a suspicion
confirmed by the finding of prominent veins in our pa-
tient’s left arm. After the second intervention, he experi-
enced a severe loss of vision in his left eye, attributed to
retinal vein branch occlusion (RVO).
Our patient’s prior history was consistent with a
hemostatic disorder. Before undergoing surgery for his
cancer-related complaints, a complete screening for risk
factors of thrombosis was performed. The levels of C and
S proteins were in the normal range; his serum Hcy level
was 25μmol/L. A subsequent molecular analysis showed
homozygosity for the MTHFR C677T mutation. He did
not have the Leiden variant of factor V. Treatment with
folic acid (25mg/day intramuscularly (i.m.)), cocarboxylase
(38mg/day, i.m.), pyridoxine hydrochloride (300mg/day,
i.m.), hydroxocobalamin (5000μg/day, i.m.), and antiplate-
let therapy with low-dose aspirin was started. After his
serum Hcy level had decreased to 18μmol/L, he under-
went a right hemicolectomy. Low-dose aspirin therapy
was maintained. Anesthesia was performed with sevoflur-
ane in 40% O2, without the use of nitrous oxide (N2O).
The operative course was uneventful and there were
no immediate or late complications as determined in a
physical examination, molecular laboratory analysis,
blood test, and Doppler ultrasound screening of the
upper and lower extremities performed 7 days, 15
days, 1 month, 3 months, and 6 months postopera-
tively. His serum Hcy levels were 13μmol/L, 11.5μmol/L,
10.4μmol/L, 9.8μmol/L, and 8.7μmol/L, respectively.
Antithrombotic therapy after surgery consisted of
100mg of intravenous acetylsalicylic acid every 24 hours
starting 12 hours after the end of the surgery. On day 3,
our patient resumed oral therapy with low-dose aspirin.
The administration of B vitamins continued with high
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by oral folic acid (15mg/day) and hydroxocobalamin
(5μg/day) for maintenance.
Discussion
The suspicion that our patient had a genetically deter-
mined hemostatic alteration arose when his anamnesis in-
cluded thrombotic complications after previous surgeries.
DVT of the upper extremity is a rare event, accounting
for only 1-4% of DVTs [6]. This complication is usually
associated with the placement of a central venous cath-
eter [7]; however, this was not the case in our patient, in
whom the device was never implanted. His report of
RVO led us to investigate the clinical aspects and patho-
genesis underlying his medical history. HHcy was re-
cently identified as an emerging risk factor for RVO.
Although the main risk factors are hypertension and
glaucoma, elevated serum Hcy levels are a more fre-
quent occurrence than other known risk factors for car-
diovascular diseases (for example, diabetes, dyslipidemia,
smoking, hyperviscosity syndrome, and vasculitis) in pa-
tients with RVO. This association is supported by the
high frequency of homozygosity for the C677T MTHFR
gene polymorphism in patients with RVO [8, 9].
Once the diagnosis of thrombophilic disease was
established, an appropriate peri-operative protocol was
chosen. Surgery and its related stress can alter the pa-
tient’s hemostatic balance; this is especially the case in
cancer patients. Indeed, the increased risk of thrombo-
embolism in cancer patients has long been recognized,
and it has been attributed to the complex state of hyper-
coagulability. Chemotherapy enhances the risk of throm-
bosis by causing endothelial damage.
Cancer-related thrombosis is the second leading cause
of death (after cancer itself ) in cancer patients and is ac-
companied by a marked worsening of the prognosis [10].
Therefore, in this cohort of patients, it is of fundamental
importance to promptly identify additional factors lead-
ing to an increased thrombophilic risk, as this will insure
a timely intervention aimed at minimizing thrombotic
complications during the postoperative period.
Peri-operative changes in hemostasis have a multifactorial
origin but may also be secondary to medications, including
anesthetic agents. In fact, most anesthetics, including those
administered intravenously, volatile anesthetics, and local
anesthetics, have been linked to the inhibition of platelet
function, albeit to varying extents [11, 12].
The anesthetic agent with the greatest impact on folate
metabolism is N2O, which deactivates cobalamin via an
oxidation reaction and causes an irreversible block of
MET synthase, located at the confluence of Hcy methy-
lation and the folate cycle. This results in a sustained in-
crease in plasma Hcy concentrations and in the absence
of biologically active folate (‘folate trapping’) that can beused for the conversion of Hcy to MET [13]. There-
fore, N2O-induced MET synthase inhibition in patients
with MTFR mutations can cause severe hematological
and neurological effects and the use of N2O during
anesthesia should therefore be avoided in this cohort.
Over the last 30 years, more than a dozen clinical
cases have been published in which N2O anesthesia led
to neurological complications, including myelopathy,
peripheral neuropathy, and hemiparesis, caused by a lack
of MET in the brain [14, 15].
The neurological damage caused by N2O is often ac-
companied by hematological abnormalities, such as meg-
aloblastic anemia and bone marrow disorders. Selzer et al.
[16] proposed the ‘double-hit’ mechanism to explain the
neurological deterioration and death of a child anesthe-
tized twice with N2O. This hypothesis links HHcy and the
N2O-induced inhibition of folate metabolism with a defect
in the MTHFR gene. Our case study suggests that the
‘double-hit’ hypothesis is also applicable to patients with a
cobalamin or folate deficiency who are exposed to N2O,
for example, patients with other MTHFR gene polymor-
phisms [17]. Thus, in patients in whom altered Hcy
metabolism is suspected, a more in-depth molecular diag-
nosis and, if the surgical intervention cannot be post-
poned, the avoidance of N2O-containing anesthesia are
recommended.
Badner et al. described an association between Hcy and
a significant increase in the incidence and duration of post-
operative ischemia in patients receiving N2O-containing
anesthesia for carotid endarterectomy [18].
Although the inhibition of cobalamin and HHcy after
N2O administration is transient, lasting only for a few
days [19], the effect coincides with the postoperative
period, during which the patient is particularly vulner-
able, as evidenced by the very high risk of serious cardio-
vascular complications on postoperative days 2 and 3
[20, 21]. In addition, Hcy levels seem to correlate with
the duration of N2O exposure. The preoperative admin-
istration of B vitamins can prevent the effects induced
by N2O [22].
In the ENIGMA study, patients undergoing noncardiac
surgery who were at low cardiovascular risk and exposed
to N2O had an unexpectedly high number of myocardial
infarctions [23]. Recent studies have also shown that pa-
tients homozygous for the MTHFR mutation who receive
N2O anesthesia have higher postoperative plasma Hcy
levels than patients who are heterozygous for the muta-
tion or carry the wild-type gene [24].
In contrast to previous work, Nagele et al. [25] sug-
gested that neither N2O-induced HHcy nor MTHFR
gene polymorphisms are associated with postoperative
cardiac events. This implies a minor role for genetic in-
fluences in the response to anesthesia and that the
prophylactic use of B vitamins would thus be effective in
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not peri-operative cardiac events.
To determine the true impact of N2O on cardiovascu-
lar events requires a large and rigorous study. The re-
sults of ENIGMA II, in which 7000 patients undergoing
major surgery were enrolled, supports the safety profile
of N2O for use in major noncardiac surgery, although
these patients had normal Hyc values [26].
Another consideration related to the MTHFR muta-
tion is its association with colorectal cancer and its
interference with chemotherapy. MTHFR plays an im-
portant role in folate metabolism, which has been impli-
cated in carcinogenesis because of the folate dependence
of methylation, repair, and DNA synthesis. In previous
work, we analyzed the relationship between C677T and
A1298C MTHFR gene polymorphisms and the bio-
logical, pathological, genetic, and epigenetic characteris-
tics of several different tumor types and their response
to chemotherapy with 5-fluorouracil. The aim of that
study was to determine the contribution of the MTHFR
genotype to the susceptibility to colorectal cancer and
the response to treatment [27–29]. While some authors
have reported the protective effect of the allelic variant
C677T in the development of several cancers [27, 28],
the meta-analysis of Pu et al. showed an association be-
tween this polymorphism and an increased susceptibility
to ovarian cancer in the Asian population [29]. In
addition, the MTHFR A1298C polymorphism is report-
edly associated with a high risk of colon cancer [30], but
according to the meta-analysis of Zhao et al. [31] both the
MTHFR 677T and the 1298C alleles are associated with a
low risk of colorectal cancer. This finding further empha-
sizes the uniqueness of our case because we found the
C677T mutation in our patient. Both polymorphisms may
also be influenced by independent factors that in turn de-
termine the response to 5-fluorouracil. Thus, MTHFR
genotyping may guide the selection of the optimal treat-
ment regimen [32].
Conclusions
Patients with neoplastic disease frequently undergo sur-
gery, followed by the administration of chemotherapy. Be-
cause these three factors are known to alter hemostatic
balance, the suspicion of a thrombophilic disease in a can-
cer patient must include a thorough laboratory diagnostic
evaluation. If elevated serum Hcy levels are found, a
complete screening, including a molecular analysis aimed
at identifying the type of genetic mutation, is warranted.
Our case study also emphasizes the importance of a
multidisciplinary approach. Multicenter studies have
sought to quantify the cardiovascular complications as-
sociated with the use of N2O in patients with HHcy. The
ENIGMA II study showed that N2O does not increase
the risk of death and cardiovascular complications orsurgical site infection in patients undergoing major non-
cardiac surgery. However, these results are valid only for
patients with normal Hyc values. Whether MTHFR gene
polymorphisms are associated with an increased risk of
N2O-induced cardiac events remains to be determined. In
the meantime, however, the use of N2O in these patients
should be avoided and the thrombophilic effect of HHcy
minimized using acetylsalicylic acid prophylaxis, folic acid,
and B vitamins. Finally, our results have oncological impli-
cations, as they suggest that MTHFR polymorphisms in-
fluence the susceptibility to colorectal cancer.
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